Jean G MacFadyen
Overview
Explore the profile of Jean G MacFadyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
10336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nordestgaard A, Pradhan A, Everett B, MacFadyen J, Bhatt D, Visseren F, et al.
Eur Heart J
. 2025 Feb;
PMID: 39950981
Background And Aims: Guidelines focus on individuals with triglycerides between 2.3 and 5.6 mmol/L (200 and 499 mg/dL). The hypotheses that triglycerides across the full biological range and within this...
2.
Associations of Serum Urate and Cardiovascular Events in a Clinical Trial of Interleukin-1β Blockade
Adamstein N, MacFadyen J, Weber B, Libby P, Solomon D, Ridker P
JACC Adv
. 2025 Jan;
4(3):101583.
PMID: 39862678
Background: Serum urate (SU) associates with cardiovascular (CV) events, mortality, and gout. Objectives: The purpose of this study was to assess whether SU predicts CV risk in a trial of...
3.
Marinho L, Everett B, Aday A, Visseren F, MacFadyen J, Zaharris E, et al.
J Am Coll Cardiol
. 2024 Jul;
84(4):408-410.
PMID: 39019534
No abstract available.
4.
Ridker P, Bhatt D, Pradhan A, Glynn R, MacFadyen J, Nissen S
Lancet
. 2023 Mar;
401(10384):1293-1301.
PMID: 36893777
Background: Inflammation and hyperlipidaemia jointly contribute to atherothrombotic disease. However, when people are treated with intensive statin therapy, the relative contributions of inflammation and hyperlipidaemia to the risk of future...
5.
Pradhan A, Glynn R, Fruchart J, MacFadyen J, Zaharris E, Everett B, et al.
N Engl J Med
. 2022 Nov;
387(21):1923-1934.
PMID: 36342113
Background: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated...
6.
Ridker P, Tuttle K, Perkovic V, Libby P, MacFadyen J
Eur Heart J
. 2022 Aug;
43(46):4832-4844.
PMID: 35943897
Aims: Hyperlipidaemia and inflammation jointly contribute to atherosclerotic disease. Yet, after the initiation of statin therapy, the relative contributions of these processes may differ in patient groups, such as those...
7.
Yoshida K, Glynn R, Choi H, Everett B, Li Y, MacFadyen J, et al.
Arthritis Care Res (Hoboken)
. 2021 Dec;
75(4):817-824.
PMID: 34874116
Objective: The objective of this study was to quantify the value of early suppression of high-sensitivity C-reactive protein (hsCRP) levels as a biomarker of the protective role of canakinumab against...
8.
Xu C, Selhub J, Jacques P, Paynter N, MacFadyen J, Glynn R, et al.
Rheumatology (Oxford)
. 2021 Jun;
60(6):2963-2968.
PMID: 34144603
Objectives: Methotrexate is widely used at low dosages (LD-MTX) for non-oncologic indications and is associated with a variety of adverse effects (AEs). We sought to determine whether concentrations of the...
9.
Adamstein N, MacFadyen J, Rose L, Glynn R, Dey A, Libby P, et al.
Eur Heart J
. 2021 Jan;
42(9):896-903.
PMID: 33417682
Aims: The neutrophil-lymphocyte ratio (NLR) is a readily available inflammatory biomarker that may associate with atherosclerosis and predict cardiovascular (CV) events. The aims of this study are to determine whether...
10.
Everett B, MacFadyen J, Thuren T, Libby P, Glynn R, Ridker P
J Am Coll Cardiol
. 2020 Oct;
76(14):1660-1670.
PMID: 33004131
Background: Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab significantly reduces the first major adverse cardiovascular event in patients with prior myocardial infarction (MI) and residual inflammatory risk (high-sensitivity C-reactive...